The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): First results of phase II trial GORTEC 2008-03.
J. Guigay
Consultant or Advisory Role - Merck Serono; Sanofi
Honoraria - Merck Serono; Sanofi
Research Funding - Chugai Pharma; Merck Serono; Novartis; Sanofi
J. Fayette
Honoraria - Sanofi
A. Dillies
No relevant relationships to disclose
C. Sire
No relevant relationships to disclose
J. N. Kerger
No relevant relationships to disclose
I. Tennevet
No relevant relationships to disclose
J. H. Machiels
Consultant or Advisory Role - Boehringer Ingelheim; Genmab; Merck Serono
Research Funding - Merck Serono; Novartis
S. Zanetta
No relevant relationships to disclose
Y. Pointreau
No relevant relationships to disclose
L. Bozec Le Moal
No relevant relationships to disclose
L. Brugel Ribere
No relevant relationships to disclose
S. Henry
No relevant relationships to disclose
S. Temam
No relevant relationships to disclose